Autologous mesenchymal stem cell transplantation for end-stage liver cirrhosis :a Meta-analysis
Xiaoyan Zhang,Zhiyan Li,Bo Yan,Xiaoqing Kuang,Hailin Tang,Nian Fu
DOI: https://doi.org/10.13406/j.cnki.cyxb.001316
2018-01-01
Abstract:Objective:To effective evaluate the previous controlled clinical trials of bone marrow mesenchymal stem cells(BM-MSCs) transplantation for end-stage liver cirrhosis validity assessment.Methods:Wanfang database (1990.01-2016.05),CNKI (1990.01-2016.05),PubMed (1990.01-2016.05),Embase (1990.01-2016.05),The Cochrane Library (Issue 5,2016),Science direct (1990.01-2016.05),Medline(1990.01-2016.05) were retrieved for publication in all languages and relevant literature and experiments designed for randomized controlled trial (RCT).All enrolled publication met the requirements according to the inclusion and exclusion criteria.Meta-analysis was performed by using Review Manager 5.3 software and end-stage liver disease (MELD) score,prothrombin time international normalized ratio(INR),aspertate aminotransferase(AST) were taken as the main analyzing indicators.Results:Eight references were enrolled including a total of 507 patients with liver cirrhosis (255 cases of control group,252 cases of BM-MSCs treatment group).Compared with those of control group,BM-MSCs transplantation in patients with decompensated cirrhosis MELD score (MD=1.65,95 ％ CI=2.8 to 0.50,P=0.005),AST (MD =0.26,95％CI=0.44 to 0.08,P=0.005),INR (MD=0.26,95％CI=0.44 to 0.08,P=0.005) significantly decreased after 1 month;BM-MSCs treatment effect were superior to that of control group after six months:MELD score(MD=1.65,95％CI=2.80 to 0.50,P=0.005),AST(MD=0.26,95％CI=0.44 to 0.08,P=0.005),INR(MD=0.26,95％CI=0.44 to 0.08,P=0.005).Conclusion:Due to the potential of the immune regulation of BM-MSCs and its differentiation into liver cells,BM-MSCs can be used as a promising therapeutic agent for liver cirrhosis.And the current study found that this therapy can be safe and effective in improving liver function.However,how to control different variables to optimize the treatment of cirrhosis of the liver is not clear,therefore,cirrhosis optimize treatment strategies need to be further explored in future clinical trials and research mechanisms.